$PFE $CELG $GILD: Pfizer Opts To Defer Price Hikes Amid Trump Scrutiny — So, Who’s Next?

Date: Wednesday, July 11th, 2018

Stock(s) mentioned: , ,

Source: Investor’s Business Daily (http://www.investors.com)

Summary:

An agreement by Dow Jones component Pfizer to defer drug price increases in an effort to play nice with President Donald Trump led analysts Wednesday to question what the fallout of the drug giant’s action would be for the industry.

The post Pfizer Opts To Defer Price Hikes Amid Trump Scrutiny — So, Who’s Next? appeared first on Investor’s Business Daily.

Full article address: https://www.investors.com/news/technology/pfizer-restructuring-price-increases/

Latest News:

$FCAU $RACE $CNHI: Fiat Chrysler Names Jeep Chief Manley To Replace CEO Marchionne

$BA $EADSY $FDX $LMT: Boeing 797 Doubts And 4 Other Things You May Have Missed At Farnborough

$LOXO $BPMC $DCPH $NVS $PFE: How These Biotech Companies Hope To Fight Cancer With Precision Medicine

$GSK $NVS: GlaxoSmithKline Reportedly Mulling A Spinoff Of Consumer Unit

$ISRG $JNJ $MDT $MZOR $ZBH: Will A ‘Moat’ Continue Protecting This Big Cap 20 From Rivals?

$SPOT $P $GOOGL $AMZN $AAPL: Spotify Stock Gets Price-Target Hikes Ahead Of Earnings Report

$FB: Facebook Stock Hits Record High As Advertising Prospects Hailed

$MRK $PFE: Dow’s Merck Falls In Line Behind Pfizer On Drug-Pricing Plans

$NFLX: Netflix Subscribers Upgrading To Premium Service Tier

$BA $EADSY $FDX $LMT: 5 Things That Flew Below The Radar At The Farnborough Airshow

$GE $HON $UTX $BHGE: GE Stock Dives On Cash Target; Honeywell Earnings Top

Related News:

$BIIB $GILD $REGN $ALXN $CELG: Biotechs Brace For Mixed Earnings Amid ‘Sparse’ Drug Price Increases

$CELG $NVS $BIIB $MYL $TEVA: How Celgene Could Win Big On A Patent Victory For Rival Novartis

$XLRN $CELG $BLUE $CRSP $VRTX: Why This Partnership Could Help Stoke More Confidence For Celgene

$XLRN $CELG $BIB: Acceleron Pharma Soars On Celgene-Partnered Anemia Treatment

$XLRN $CELG $BIB: Acceleron Pharma Soars On Celgene-Partnered Anemia Treatment

$CELG $BIIB $GILD $IBB $XBI: Big Biotechs May Lose Ground To Smaller Upstarts This Year

$ALDR $AMGN $CELG $TEVA $LLY: Why Alder’s CEO Hire Could Indicate It’s Seeking A Buyer

$RHHBY $CELG $JNJ: Roche Has Mixed News In Lung Cancer Tests With Celgene, Dow’s J&J

$CELG: Celgene Hammered, Again, On ‘Subpar’ Success In Developing Drugs

$CELG $MYL $RDY $BLUE $GILD: Analysts Split: Celgene Tilts ‘To Greater Risk’ On Revlimid Challenges

$AMGN $CELG $BIIB $PFE $NVS: Why Amgen’s In Trouble — And Should Take Notes From Biogen, Celgene